Cover Image
市場調查報告書

肺支氣管發育不良 : 開發平台分析

Bronchopulmonary Dysplasia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213096
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
肺支氣管發育不良 : 開發平台分析 Bronchopulmonary Dysplasia - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 53 Pages
簡介

肺支氣管發育不良是慢性疾病之一,是出生時接受人工呼吸器治療之早產兒中惡化的疾病之一。症狀有呼吸急促,心搏過速,更進一步的呼吸困難,皮膚發青色等。原因有先天性心臟病,嚴重呼吸感染疾病/肺感染疾病等。

本報告提供肺支氣管發育不良的治療藥開發情形相關調查,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

肺支氣管發育不良概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肺支氣管發育不良:企業開發中的治療藥

肺支氣管發育不良:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

肺支氣管發育不良:企業開發中的產品

肺支氣管發育不良的治療藥開發企業

  • Airway Therapeutics, Inc.
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Mallinckrodt Plc
  • MediPost Co., Ltd.
  • Syntrix Biosystems, Inc.
  • Therabron Therapeutics, Inc.

肺支氣管發育不良:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AT-100
  • budesonide
  • CG-100
  • Drugs for Bronchopulmonary Dysplasia
  • gefitinib
  • nitric oxide
  • Pneumostem
  • R-190
  • R-801
  • R-901
  • R-908
  • SX-576
  • Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders

肺支氣管發育不良:最近的開發平台趨勢

肺支氣管發育不良:暫停中的計劃

肺支氣管發育不良:開發中止的產品

肺支氣管發育不良:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9110IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2017, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. The predisposing factors include congenital heart disease and severe respiratory or lung infection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 9 and 2 respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchopulmonary Dysplasia - Overview
    • Bronchopulmonary Dysplasia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Bronchopulmonary Dysplasia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
    • Airway Therapeutics LLC
    • Chiesi Farmaceutici SpA
    • MediPost Co Ltd
    • Meridigen Biotech Co Ltd
    • Syntrix Biosystems Inc
    • Therabron Therapeutics Inc
  • Bronchopulmonary Dysplasia - Drug Profiles
    • AT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pneumostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-190 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapies for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchopulmonary Dysplasia - Dormant Projects
  • Bronchopulmonary Dysplasia - Discontinued Products
  • Bronchopulmonary Dysplasia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
      • May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants
      • May 03, 2016: MEDIPOST receives US Patent for 'PNEUMOSTEM' for Treating Lung Disease
      • Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth
      • Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform
      • Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate
      • Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial
      • Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform
      • Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program
      • May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia
      • Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
      • Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
      • Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage'
      • Feb 06, 2014: Stem cells to treat lung disease in preterm infants
      • Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bronchopulmonary Dysplasia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H1 2017
  • Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2017
  • Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, H1 2017
  • Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, H1 2017
  • Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, H1 2017
  • Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics Inc, H1 2017
  • Bronchopulmonary Dysplasia - Dormant Projects, H1 2017
  • Bronchopulmonary Dysplasia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Bronchopulmonary Dysplasia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top